C

    Cellectis SA (CLLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.35
    -0.05 (-1.47%)

    Market Cap: $342.38M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    +0.77%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.23 - $-0.15
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.22-7.3%
    60d ago$-0.22-10.6%
    30d ago$-0.22-10.6%
    7d ago$-0.22-10.6%
    Current$-0.20
    Revenue Consensus
    $13M
    Range$9M - $17M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.46 - $0.20
    6 analysts
    Revenue Consensus
    $16M
    Range$-2162390 - $34M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.20---
    Jun 26
    		$-0.22$-0.25+12.00%Beat+0.0%
    Mar 26
    		$-0.18$-0.26+30.77%Beat-5.9%
    Dec 25
    		$-0.24$-0.29+18.59%Beat-50.0%
    Sep 25
    		$0.02N/A+120.00%Beat+109.1%
    Jun 25
    		$-0.22$-0.15-46.67%Miss+18.5%
    Mar 25
    		$-0.17$-0.16-6.25%Miss-21.4%
    Dec 24
    		$-0.16$-0.09-77.78%Miss+77.1%
    Sep 24
    		$-0.22$-0.24+8.33%Beat+40.5%
    Jun 24
    		$-0.27$-0.27+0.00%Beat-80.0%
    Mar 24
    		$-0.14$-0.27+48.15%Beat+74.5%
    Dec 23
    		$-0.70$-0.22-218.18%Miss-18.6%
    Sep 23
    		$-0.37$-0.36-2.78%Miss+41.3%
    Jun 23
    		$-0.15N/A+55.88%Beat+64.3%
    Mar 23
    		$-0.55$-0.42-30.95%Miss+21.4%
    Dec 22
    		$-0.59$-0.71+16.90%Beat-7.3%
    Sep 22
    		$-0.63$-0.21-200.00%Miss+23.2%
    Jun 22
    		$-0.42$-0.57+26.32%Beat+52.3%
    Mar 22
    		$-0.70$-0.66-6.06%Miss-150.0%
    Dec 21
    		$-0.55$-0.92+40.22%Beat+42.1%
    Sep 21
    		$-0.82$-0.75-9.33%Miss-15.5%
    Jun 21
    		$-0.88$-0.65-35.38%Miss-15.8%
    Mar 21
    		$-0.28N/A+61.11%Beat-159.6%
    Dec 20
    		$-0.95$-0.78-21.79%Miss-8.0%
    Sep 20
    		$-0.71$-0.50-42.00%Miss-208.7%
    Jun 20
    		$-0.76$-0.74-2.70%Miss-16.9%
    Mar 20
    		$0.47$-0.65+172.31%Beat+280.8%
    Dec 19
    		$-0.88$-0.73-20.55%Miss-66.0%
    Sep 19
    		$-0.23$-0.42+45.24%Beat+36.1%
    Jun 19
    		$-0.65$-0.36-80.56%Miss-2266.7%
    Mar 19
    		$-0.26$-0.32+18.75%Beat+33.3%
    Dec 18
    		$-0.53$-0.71+25.35%Beat+30.3%
    Sep 18
    		$-0.36$-0.31-16.13%Miss+2.7%
    Jun 18
    		$0.03N/A+108.82%Beat+107.0%
    Mar 18
    		$-0.39$-0.38-2.63%Miss-129.4%
    Dec 17
    		$-0.76$-0.72-5.56%Miss-100.0%
    Sep 17
    		$-0.37$-0.34-8.82%Miss-3600.0%
    Jun 17
    		$-0.43$-0.22-95.45%Miss-
    Mar 17
    		$-0.17N/A+54.05%Beat-
    Dec 16
    		$-0.38$-0.38+0.00%Beat-
    Sep 16
    		$-0.01N/A+97.44%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.40EV/EBITDA-3.90x
    Price/FCF-7.65xFCF Yield-13.07%
    Profitability
    Profit Margin-102.30%Operating Margin-340.70%
    ROE-94.50%ROIC-74.14%
    Financial Health
    Debt/Equity1.31xInterest Coverage-8.85x
    Current Ratio1.37xQuick Ratio1.37x
    Trading Statistics
    Beta2.75Avg Volume19.31K
    52-Week High$5.4852-Week Low$2.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.34
    SMA 20$3.12
    SMA 50$2.98
    SMA 200$3.70
    EMA 10$3.32
    EMA 20$3.20
    EMA 50$3.12
    EMA 200$3.29

    MACD

    Line: 0.14Signal: 0.11Hist: 0.03

    ADX

    ADX: 14.0+DI: 25.3-DI: 21.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down32.0
    PSAR$3.02

    Bollinger Bands

    Upper Band$3.67
    Lower Band$2.57
    %B Position3526%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    57.1

    Momentum Oscillators

    Stoch %K82.2
    Stoch %D88.7
    Williams %R-30.1
    ROC (10d)7.7%
    Momentum0.24
    CCI (20d)78.4
    MFI (14d)48.8

    Volatility Measures

    ATR (14d)$0.19(5.7%)
    StdDev (20d)0.28
    Hist Vol71.4%(High)

    Volume Flow

    VWAP$3.39
    OBV-7.5M
    AD Line-3.8M
    CMF (20d)0.252

    Volume Metrics

    Avg Vol (20d)20.1K
    Vol Ratio0.7x
    VWMA (20d)$3.05

    Pivot Points

    R3$3.68
    R2$3.63
    R1$3.51
    Pivot Point$3.46
    S1$3.34
    S2$3.29
    S3$3.17

    Advanced Oscillators

    TSI19.58
    Ultimate Osc53.2
    KST153.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.22M$5.80M$10.40M$35.17M$16.73M$10.65M$12.72M$16.20M$8.06M$4.53M$285,392$155,000
    Cost of Revenue$4.41M$4.55M$3.00M$2.36M$2.42M$2.02M$2.52M$2.79M$1.53M$2.35M$5.39M$181,000
    Gross Profit$815,868$1.25M$7.40M$32.81M$14.30M$8.64M$10.20M$13.41M$6.53M$2.18M$-5,102,783$-26,000
    Operating Expenses$26.27M$28.35M$24.75M$24.77M$23.89M$22.82M$20.88M$24.18M$23.74M$23.08M$25.91M$20.64M
    R&D$20.89M$23.09M$24.44M$24.07M$23.08M$21.93M$20.87M$23.83M$23.52M$22.32M$25.74M$19.07M
    SG&A$3.03M$2.91M$1.50M$2.48M$2.29M$2.33M$934,000$2.01M$2.35M$2.37M$4.67M$3.23M
    Operating Income$-25,450,716$-27,099,145$-17,351,000$8.04M$-9,587,000$-14,179,000$-10,680,000$-10,769,000$-17,211,000$-20,894,000$-31,007,983$-20,671,000
    Interest Income$1.55M$1.84M$2.08M$2.31M$2.19M$2.91M$3.57M$3.02M$2.77M$1.92M$1.45M$723,000
    Interest Expense$2.01M$2.27M$2.03M$2.11M$2.08M$1.91M$1.71M$2.15M$1.83M$1.79M$17.71M$1.62M
    Income Before Tax$-23,436,509$-19,560,843$-26,742,000$589,000$-23,736,000$-18,127,000$6.44M$-23,117,000$-25,463,000$5.38M$-64,906,200$-17,376,000
    Income Tax Expense$-1,647,715$-1,731,270$-423,000$0$-1,000$1,000$514,000$-59,000$-193,000$-262,000$-746,256$106,000
    Net Income$-21,788,793$-17,829,573$-26,318,000$589,000$-23,735,000$-18,128,000$5.92M$-23,056,000$-25,270,000$5.64M$-43,224,411$-17,482,000
    EBITDA$-21,044,825$-22,547,661$-19,605,000$7.71M$-16,664,000$-11,285,000$14.17M$-16,475,000$-18,900,000$11.74M$-25,782,168$-11,400,000
    EBIT$-25,450,716$-27,099,145$-24,708,000$2.70M$-21,681,000$-16,216,000$8.35M$-21,195,000$-23,628,000$7.17M$-31,007,983$-15,866,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLLS

    News

    Cellectis S.A. (NASDAQ:CLLS) Given Consensus Rating of "Moderate Buy" by Analysts

    Cellectis S.A. (NASDAQ:CLLS) has received a consensus rating of "Moderate Buy" from analysts, with an average 12-month price target of $7.00. Despite exceeding EPS estimates in its latest quarter with an adjusted loss of $0.22 per share, the company's revenue of $6.9 million missed analyst expectations. Institutional investors hold a significant portion of Cellectis stock, owning 63.9% of the shares.

    MarketBeat•8/11/26•
    Somewhat-Bullish

    Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

    Analysts have significantly cut their revenue and earnings per share estimates for Cellectis S.A. (EPA:ALCLS) following the company's recent quarterly results. Revenues for 2026 are now expected to decline by 19% to US$51.8m, and losses per share are projected to increase slightly to US$0.87. The consensus price target also fell by 59% to €6.50, reflecting concerns about the company's intrinsic value and underperformance compared to the wider industry.

    Simply Wall Street•8/9/26•
    Neutral

    Barclays Initiates Cellectis(CLLS.US) With Buy Rating, Announces Target Price $9

    Barclays has initiated coverage of Cellectis (CLLS.US) with a Buy rating. The firm has set a price target of $9 for the company's stock.

    Moomoo•8/8/26•
    Bullish

    Cellectis Reports Financial Results for the Second Quarter 2026

    Cellectis, a clinical-stage biotechnology company, reported its financial results for the second quarter of 2026

    The Manila Times•8/7/26•
    Bullish

    Cellectis earnings beat by $0.04, revenue fell short of estimates

    Cellectis (NASDAQ: CLLS) reported its second-quarter earnings, beating analyst EPS estimates by $0.04 with a figure of $-0.220. However, the company's revenue of $6.9M fell short of the consensus estimate of $10.97M. Despite recent negative EPS revisions, Cellectis's stock performance shows a 1.130% increase over the last 12 months, with its financial health rated as "good performance" by InvestingPro.

    Investing.com•8/7/26•
    Somewhat-Bullish

    Frequently Asked Questions About CLLS

    Does CLLS pay dividends?
    Cellectis SA (CLLS) does not currently pay a regular dividend.
    What is CLLS's market cap?
    Cellectis SA (CLLS) has a market capitalization of $342.38M with a current stock price of $3.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In